These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3133689)

  • 1. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.
    Kasvikis Y; Marks IM
    Psychopharmacology (Berl); 1988; 95(1):113-8. PubMed ID: 3133689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome.
    Stern RS; Marks IM; Mawson D; Luscombe DK
    Br J Psychiatry; 1980 Feb; 136():161-6. PubMed ID: 7370482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
    Stern RS; Marks IM; Wright J; Luscombe DK
    Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
    Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.
    Marks IM; Lelliott P; Basoglu M; Noshirvani H; Monteiro W; Cohen D; Kasvikis Y
    Br J Psychiatry; 1988 Apr; 152():522-34. PubMed ID: 3167404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clomipramine and exposure for obsessive-compulsive rituals: i.
    Marks IM; Stern RS; Mawson D; Cobb J; McDonald R
    Br J Psychiatry; 1980 Jan; 136():1-25. PubMed ID: 6986939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial.
    Monteiro WO; Noshirvani HF; Marks IM; Lelliott PT
    Br J Psychiatry; 1987 Jul; 151():107-12. PubMed ID: 3315086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Stern RS; Cobb JP; Marks IM; Jones RB; Luscombe DK
    Postgrad Med J; 1977; 53 Suppl 4():97-103. PubMed ID: 341110
    [No Abstract]   [Full Text] [Related]  

  • 10. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison.
    Leonard HL; Swedo SE; Rapoport JL; Koby EV; Lenane MC; Cheslow DL; Hamburger SD
    Arch Gen Psychiatry; 1989 Dec; 46(12):1088-92. PubMed ID: 2686576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
    Insel TR; Murphy DL; Cohen RM; Alterman I; Kilts C; Linnoila M
    Arch Gen Psychiatry; 1983 Jun; 40(6):605-12. PubMed ID: 6342562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders.
    Amin MM; Ban TA; Pecknold JC; Klingner A
    J Int Med Res; 1977; 5 Suppl 5():33-7. PubMed ID: 340305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis.
    Ananth J; Pecknold JC; van den Steen N; Engelsmann F
    Prog Neuropsychopharmacol; 1981; 5(3):257-62. PubMed ID: 7022517
    [No Abstract]   [Full Text] [Related]  

  • 18. Clomipramine in the elderly: tolerance and plasma levels.
    Kunik ME; Pollock BG; Perel JM; Altieri L
    J Geriatr Psychiatry Neurol; 1994; 7(3):139-43. PubMed ID: 7916936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine.
    Linnoila M; Insel T; Kilts C; Potter WZ; Murphy DL
    Clin Pharmacol Ther; 1982 Aug; 32(2):208-11. PubMed ID: 7094507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.